exon of the cystic fibrosis transmembrane regulator (CFTR) gene as a standard to determine the copy number of the SMNT and SMNC genes, and incorporates the use of two internal standards (SMN-IS and CFTR-IS) to monitor the efficiency of the PCR reaction and to ensure that equal amounts of target genomic DNA are added to each tube. Since this test uses CFTR as the standard for determination of SMNT copy number, the significant limitation of using the SMNc gene (whose copy number varies in both patients and controls) as a reference is avoided. Dosage analysis of the SMNT gene in the proband showed that he possessed only a single copy of SMNT (fig 1) .
Heteroduplex analysis was then used to screen for sequence variations in the nine exons of the remaining copy of SMNT.'°An abnormal band was identified in exon 4 of SMN. Sequence analysis of patient exon 4 subclones showed a two base pair deletion of nucleotides 542-3 (GT) of the SMN gene (fig 2) . The deletion results in a frameshift and premature termination codon shortly downstream, predicting an SMN protein product containing eight altered amino acids before truncation. In order to determine whether the variant exon 4 sequence was contained within SMNI or SNC, the patient's lymphocyte RNA was amplified by RT-PCR using an exon 4 sense primer and an exon 8 antisense primer, then subcloned and sequenced. Patient subclones containing SMNT were identified by restriction enzyme digestion, and sequence analysis of these clones confirmed that the mutant transcripts were derived from SMNT. These results indicate that this type I SMA patient had two different SMNT mutations: one SMNT allele was deleted or converted, while the other contained a two base pair deletion in exon 4.
Discussion
The fact that exon 7 of the SMNT gene is not detectable in -95% of SMA patients has allowed the development of an effective PCR based assay for the diagnosis of SMA.3 '4 However, the 1 in 20 SMA patients who do not homozygously lack the SMNT gene will be missed using this test. The proband, a male infant with clinical findings consistent with a diagnosis of type I SMA (Werdnig-Hoffmann disease), is one of these patients. He inherited one deleted or converted copy of the SMNT gene and one copy containing a different mutation, a 2 base pair deletion in exon 4 which causes a frameshift and would be predicted to result in a truncated SMNT protein.
We have previously reported a quantitative PCR based assay for determination of SMNT gene copy number.'0 In addition to allowing the molecular diagnosis of SMA carriers, this test also enables us to screen patients with SMA-like clinical findings efficiently in order to help distinguish SMA compound heterozygotes from non-5q cases. Once an SMA-like patient with one copy of the SMNT gene has been identified, the probability of a 5q SMA diagnosis is increased significantly. However, it is possible that the subject may be an SMA carrier whose symptoms are caused by another neuromuscular disorder. Therefore, we recommend that mutation screening of the remaining copy of SMNT be carried out. By using this initial quantitative screen for SMNT gene copy number, the number of patients who require mutation analysis can be drastically reduced. In our experience, -10% of the patients referred to our diagnostic laboratory for SMA testing who are not homozygously lacking the SMNT gene retain a single copy of SMNT. In the remaining 90% of these SMA-like patients, the SMNT gene dosage is normal and 5q SMA is effectively ruled out as a diagnosis; in these cases the physician should consider other neuromuscular diseases. We have used this combination of an initial SMNT dosage assay and mutation detection to identify two other small mutations in the SMNT gene, a missense mutation (S262I) and an 11 base pair duplication in exon 6.7 10 Once a specific SMNT mutation has been identified in a family, other family members can be accurately diagnosed and appropriately counselled.
This screening strategy would not be as useful in diagnosing SMA in consanguineous families or in groups exhibiting a significant founder effect, since subjects who are homozygous for a non-deletion SMNT mutation would be more common in those instances. 6 Another limitation is that mutation detection in the SMNT gene is relatively technically difficult. Although a few of the SMNT mutations identified have now been found in more than one patient, there is no single common mutation which can be tested. In addition, SMNT mutations have been identified in at least four different exons of the gene; there is not one mutational hotspot which could be easily screened. The presence of the copy gene (SMNC) also complicates SMNT mutation detection. Since SMNT and SMNC are only distinguished by single nucleotide sequence changes in exons 7 and 8, either RT-PCR or long PCR based strategies must be used to show that any mutation identified exists in SMNT and not SMNC. Although mutation analysis of the SMNT gene is not as straightforward as for some genes, the actual quantity of patients to be screened is significantly reduced by the initial dosage assay and the number of SMNT exons to be analysed (nine) is feasible. This protocol of initial SMNT gene dosage analysis followed by mutation detection allows identification of SMA compound heterozygotes (patients lacking one copy of SMN' and having another mutation in their other copy), thereby increasing the sensitivity of SMA molecular diagnosis.
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